Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $308,685.28 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 133,054 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total value of $308,685.28. Following the completion of the sale, the chief executive officer directly owned 450,667 shares of the company’s stock, valued at approximately $1,045,547.44. The trade was a 22.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Joseph Oliveto also recently made the following trade(s):

• On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $1.93, for a total value of $66,629.39.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total value of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total transaction of $1,125.00.

Milestone Pharmaceuticals Stock Up 1.1%

Milestone Pharmaceuticals stock opened at $1.91 on Friday. The firm has a market cap of $162.67 million, a price-to-earnings ratio of -2.33 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm has a 50 day moving average price of $2.22 and a two-hundred day moving average price of $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. Equities analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MIST. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 26th. Finally, Wells Fargo & Company lifted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Simplify Asset Management Inc. raised its holdings in shares of Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares during the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Milestone Pharmaceuticals by 553.5% in the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares during the last quarter. Aptus Capital Advisors LLC bought a new position in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $420,000. Propel Bio Management LLC boosted its position in shares of Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after buying an additional 3,333,333 shares during the last quarter. Finally, Raymond James Financial Inc. grew its holdings in Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares in the last quarter. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.